Clario and the University of Oxford are testing a wearable device to see how effective it is at tracking subtle changes in Parkinson’s disease, with the aim of improving clinical research. Clario’s Opal wearable sensor device has demonstrated the ability to detect motor changes faster than traditional clinical…
WTX-607, an oral small molecule being developed by Wavebreak, binds to and blocks the formation of small alpha-synuclein protein clumps — toxic aggregates linked to nerve damage in  Parkinson’s disease and Lewy body dementia — in human brain tissue, according to new data released by the company. The…
People diagnosed with Parkinson’s disease in their 80s were significantly more likely to show evidence of brain buildup of amyloid-beta, a protein linked to cognitive decline in Alzheimer’s disease, than those diagnosed at a younger age, a study found. Neither group showed signs of cognitive impairment. The researchers…
Researchers have shed light on how alpha-synuclein oligomers, small soluble protein clusters linked to Parkinson’s disease, may disrupt nerve cell function by forming dynamic, reversible pores in their cell membrane. By developing a novel assay that enabled real-time visualization of how these oligomers interact with tiny artificial vesicles resembling…
Neu Health said it’s joining an incubator program that will help it expand its flagship product, a smartphone app that lets people with Parkinson’s disease and dementia track their symptoms from home, in the U.S. market. The UK-based company said it has been selected to join the U.S.
Researchers have uncovered how exposure to a common environmental pesticide may disrupt brain function in ways that contribute to Parkinson’s disease. Exposing rats to rotenone, a pesticide mostly banned in the U.S. and Canada, but still used in lake management, triggered changes in the activation of certain genes in…
Prescribing medication for Parkinson’s disease is not straightforward, but instead is influenced by a wide range of factors and behavioral drivers, according to a new study from Europe that investigated possible reasons for the choices of prescription drugs given by treating clinicians. Beyond clinical guidelines, the researchers found that…
Suppressing the immune system to reduce brain inflammation, a known contributor to Parkinson’s disease progression, may offer a promising new strategy for slowing the disease, early trial results suggest. Specifically, azathioprine, a commonly used drug that suppresses immune activity, reduced motor symptoms and improved cognitive function in people…
Crexont, an extended-release oral formulation of carbidopa and levodopa, significantly improved sleep quality in people with Parkinson’s disease. That’s according to data based on additional analysis of the Phase 3 RISE-PD trial (NCT03670953). The results were detailed in a presentation, “Conversion to CREXONT in…
U.S. researchers have identified a novel way to block a protein known as DLK, or dual leucine-zipper kinase, that may offer a promising strategy to protect neurons from degeneration — which, the team notes, could pave the way for safer and more precise treatments for neurodegenerative conditions like Parkinson’s…
Get regular updates to your inbox.
